211 related articles for article (PubMed ID: 12936969)
1. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Scaglione F; Mouton JW; Mattina R; Fraschini F
Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
Andes D; Craig WA
Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
Onyeji CO; Bui KQ; Owens RC; Nicolau DP; Quintiliani R; Nightingale CH
Int J Antimicrob Agents; 1999 Jul; 12(2):107-14. PubMed ID: 10418754
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
Madaras-Kelly KJ; Demasters TA
Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
García-Olmos M; Parra A; García-Calvo G; Ponte C; Giménez MJ; Aguilar L; Soriano F
Int J Antimicrob Agents; 2003 Jun; 21(6):568-73. PubMed ID: 12791471
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection.
Ernst EJ; Klepser ME; Petzold CR; Doern GV
Pharmacotherapy; 2002 Apr; 22(4):463-70. PubMed ID: 11939681
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
Bédos JP; Azoulay-Dupuis E; Moine P; Muffat-Joly M; Veber B; Pocidalo JJ; Vallée E
J Pharmacol Exp Ther; 1998 Jul; 286(1):29-35. PubMed ID: 9655838
[TBL] [Abstract][Full Text] [Related]
9. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
[TBL] [Abstract][Full Text] [Related]
10. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
Andes D; Craig WA
Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
Croisier D; Chavanet P; Lequeu C; Ahanou A; Nierlich A; Neuwirth C; Piroth L; Duong M; Buisson M; Portier H
J Antimicrob Chemother; 2002 Sep; 50(3):349-60. PubMed ID: 12205059
[TBL] [Abstract][Full Text] [Related]
13. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
Jones RN; Rubino CM; Bhavnani SM; Ambrose PG;
Antimicrob Agents Chemother; 2003 Jan; 47(1):292-6. PubMed ID: 12499204
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model.
Nicolau DP; Mattoes HM; Banevicius M; Xuan D; Nightingale CH
Antimicrob Agents Chemother; 2003 May; 47(5):1630-5. PubMed ID: 12709332
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
[TBL] [Abstract][Full Text] [Related]
18. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
Azoulay-Dupuis E; Bedos JP; Vallée E; Hardy DJ; Swanson RN; Pocidalo JJ
J Infect Dis; 1991 Feb; 163(2):319-24. PubMed ID: 1988515
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
Mattoes HM; Banevicius M; Li D; Turley C; Xuan D; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228
[TBL] [Abstract][Full Text] [Related]
20. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
